BioXcel Therapeutics (BTAI) Change in Accured Expenses (2017 - 2026)
BioXcel Therapeutics (BTAI) posted quarterly Change in Accured Expenses of $2.2 million for Q1 2026, up 197.62% year-over-year from $744237.4 in Q1 2025, and up 5022.22% quarter-over-quarter from -$45000.0 in Q3 2025.
BioXcel Therapeutics (BTAI) Change in Accured Expenses (2017 - 2026) Analysis & Trends
BioXcel Therapeutics' Change in Accured Expenses history runs 10 years deep, the most recent figure standing at $2.2 million for Q1 2026.
- In Q1 2026, Change in Accured Expenses rose 197.62% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $4.5 million (up 175.02% YoY), while the FY2024 annual figure was -$4.3 million, down 273.29% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at $2.2 million, up from -$45000.0 in the prior quarter.
- The five-year high for Change in Accured Expenses was $10.1 million in Q4 2022, with the low at -$4.7 million in Q1 2023.
- The 5-year median for Change in Accured Expenses is -$232000.0 (2022), against an average of $838437.5.
- The sharpest annual moves came in 2022 and 2023: Change in Accured Expenses soared 2458.33% in 2022, then slumped 588.46% in 2023.
- BioXcel Therapeutics' Change in Accured Expenses stood at $10.1 million in 2022, then slumped by 86.74% to $1.3 million in 2023, then slumped by 347.77% to -$3.3 million in 2024, then surged by 98.65% to -$45000.0 in 2025, then jumped by 5022.22% to $2.2 million in 2026.
- Business Quant data shows BTAI's Change in Accured Expenses at $2.2 million in Q1 2026, -$45000.0 in Q3 2025, and $2.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | 82.00 Mn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | 142.00 Mn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | -219.00 Mn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | -4.00 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | -8.50 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | BioXcel Therapeutics | 24.40 Mn | 24.40 Mn | 160,000.00 | 1.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.83 Mn |
| Jun 30, 2026 | 1.83 Mn |
| Mar 31, 2026 | 2.22 Mn |
| Mar 31, 2026 | 2.22 Mn |
| Sep 30, 2025 | -45,000.00 |
| Sep 30, 2025 | -45,000.00 |
| Jun 30, 2025 | 2.31 Mn |
| Jun 30, 2025 | 2.31 Mn |
| Mar 31, 2025 | -2.27 Mn |
| Mar 31, 2025 | -2.27 Mn |
| Dec 31, 2024 | -3.33 Mn |
| Dec 31, 2024 | -3.33 Mn |
| Sep 30, 2024 | -1.66 Mn |
| Sep 30, 2024 | -1.66 Mn |
| Jun 30, 2024 | 1.28 Mn |
| Jun 30, 2024 | 1.28 Mn |
| Mar 31, 2024 | -619,000.00 |
| Mar 31, 2024 | -619,000.00 |
| Dec 31, 2023 | 1.34 Mn |
| Dec 31, 2023 | 1.34 Mn |